Truist Financial Corp Trims Stake in Bristol Myers Squibb Company $BMY

Key Points

• Truist Financial Corp trimmed its stake in Bristol Myers Squibb by 6.9%, selling 89,305 shares to hold 1,202,157 shares valued at $64.84 million, and EVP David V. Elkins sold 30,000 shares in early April.
• Institutional ownership is high at 76.41%, with major funds like Vanguard, State Street and Dimensional increasing positions (Vanguard now owns ~198.7 million shares worth about $10.72 billion).
• BMS beat quarterly expectations (EPS $1.58 vs. $1.42; revenue $11.49B), set FY26 guidance of EPS 6.05–6.35, but analysts remain mixed with a consensus "Hold" and average target of $61.31; the stock yields $2.52 annually (~4.4%).

Truist Financial Corp reduced its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,202,157 shares of the biopharmaceutical company's stock after selling 89,305 shares during the period. Truist Financial Corp owned 0.06% of Bristol Myers Squibb worth $64,844,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BMY. Vanguard Group Inc. raised its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after buying an additional 2,743,759 shares during the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after buying an additional 1,855,238 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bristol Myers Squibb by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after buying an additional 1,873,618 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Bristol Myers Squibb by 8.4% in the third quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock valued at $770,116,000 after buying an additional 1,317,199 shares during the last quarter. Finally, Pzena Investment Management LLC raised its holdings in shares of Bristol Myers Squibb by 0.4% in the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock valued at $672,062,000 after buying an additional 58,129 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of several analyst reports. Cantor Fitzgerald lifted their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research note on Wednesday, April 8th. HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research note on Tuesday, March 17th. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research note on Tuesday, January 13th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an "overweight" rating and a $75.00 price objective for the company. Finally, Morgan Stanley restated an "underweight" rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average target price of $61.31.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $57.36 on Tuesday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The stock's 50 day moving average is $59.56 and its two-hundred day moving average is $54.63. The firm has a market capitalization of $117.11 billion, a PE ratio of 16.11, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.29 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.